Loading stock data…
CSBR
$5.99+0.03 (+0.50%)
Market ClosedLast close May 1
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Champions Oncology, Inc. in the Healthcare sector is trading at $5.99. The stock is currently near its 52-week low of $5.50, remaining 8.3% below its 200-day moving average. Technical signals show neutral RSI of 57 and bullish MACD crossover, explaining why CSBR maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 57) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$5.99
Potential Upside
5%
Whystock Fair Value$6.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based u...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$83.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
2.52%
Volume
Today's trading volume
6,627
Recent News
Champions Oncology Inc (CSBR) Q3 2026 Earnings Call Highlights: Record Services Revenue and ...
Despite a slight dip in total revenue, Champions Oncology Inc (CSBR) showcases strong operational performance with record core study revenue and strategic growth investments.
Champions Oncology (CSBR) Earnings Transcript
Robert Brainin: Good afternoon, and thank you for joining us for our third quarter fiscal 2026 earnings call. First, we delivered another quarter of strong operational performance, including record services revenue and our third consecutive quarter of positive adjusted EBITDA. Second, while quarterly revenue can fluctuate in our business, we remain on track for full year revenue growth and full year positive adjusted EBITDA while continuing to invest in both our data platform and our discovery therapeutics subsidiary.
Champions Oncology, Inc. Q3 2026 Earnings Call Summary
Moby summary of Champions Oncology, Inc.'s Q3 2026 earnings call
Fund Discloses $25 Million Braze Stock Investment Amid 60% Share Plunge
This SaaS provider enables brands to personalize customer engagement across digital channels using data-driven orchestration tools.
Battery Management Dumps $9 Million Zeta Stake as Shares Slide 38% Year Over Year
This marketing technology provider delivers data-driven automation and consumer insights to enterprise clients across multiple channels.